81 related articles for article (PubMed ID: 15657211)
21. The heart failure revascularisation trial (HEART): rationale, design and methodology.
Cleland JG; Freemantle N; Ball SG; Bonser RS; Camici P; Chattopadhyay S; Dutka D; Eastaugh J; Hampton J; Large S; Norell MS; Pennell DJ; Pepper J; Sanda S; Senior R; Smith D
Eur J Heart Fail; 2003 Jun; 5(3):295-303. PubMed ID: 12798827
[TBL] [Abstract][Full Text] [Related]
22. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure.
Wallhaus TR; Taylor M; DeGrado TR; Russell DC; Stanko P; Nickles RJ; Stone CK
Circulation; 2001 May; 103(20):2441-6. PubMed ID: 11369683
[TBL] [Abstract][Full Text] [Related]
23. Is it time for a randomized trial of surgical treatment of ischemic heart failure?
Jones RH
J Am Coll Cardiol; 2001 Apr; 37(5):1210-3. PubMed ID: 11300424
[No Abstract] [Full Text] [Related]
24. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
Kantor PF; Lucien A; Kozak R; Lopaschuk GD
Circ Res; 2000 Mar; 86(5):580-8. PubMed ID: 10720420
[TBL] [Abstract][Full Text] [Related]
25. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart.
Sack MN; Rader TA; Park S; Bastin J; McCune SA; Kelly DP
Circulation; 1996 Dec; 94(11):2837-42. PubMed ID: 8941110
[TBL] [Abstract][Full Text] [Related]
26. Myocardial metabolic manipulation: a new therapeutic approach in heart failure?
O'Meara E; McMurray JJ
Heart; 2005 Feb; 91(2):131-2. PubMed ID: 15657211
[TBL] [Abstract][Full Text] [Related]
27. The heart metabolism: pathophysiological aspects in ischaemia and heart failure.
Abozguia K; Shivu GN; Ahmed I; Phan TT; Frenneaux MP
Curr Pharm Des; 2009; 15(8):827-35. PubMed ID: 19275646
[TBL] [Abstract][Full Text] [Related]
28. Modulation of myocardial energetics: An important category of agents in the multimodal treatment of coronary artery disease and heart failure.
Dalal JJ; Mishra S
Indian Heart J; 2017; 69(3):393-401. PubMed ID: 28648439
[TBL] [Abstract][Full Text] [Related]
29. Metabolic modulation as a target for heart failure treatment: current perspective.
Chenniapan S; Manchanda SC
Indian Heart J; 2007; 59(4):370-4. PubMed ID: 19126947
[No Abstract] [Full Text] [Related]
30. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism.
Lopaschuk GD
Am J Cardiol; 1998 Sep; 82(5A):14K-17K. PubMed ID: 9737481
[TBL] [Abstract][Full Text] [Related]
31. Trimetazidine in the myocardial cell mechanisms of cytoprotection.
Labrid C
Rom J Intern Med; 1998; 36(3-4):137-44. PubMed ID: 10822510
[TBL] [Abstract][Full Text] [Related]
32. Metabolic therapy for ischemic heart disease: the rationale for inhibition of fatty acid oxidation.
Stanley WC; Sabbah HN
Heart Fail Rev; 2005 Dec; 10(4):275-9. PubMed ID: 16583175
[No Abstract] [Full Text] [Related]
33. [Trimetazidine (Preductal). A new approach in controlling myocardial ischemia].
Eliseev OM
Ter Arkh; 1996; 68(8):57-63. PubMed ID: 9019836
[No Abstract] [Full Text] [Related]
34. Modulation of myocardial metabolism: an emerging therapeutic principle.
Horowitz JD; Chirkov YY; Kennedy JA; Sverdlov AL
Curr Opin Cardiol; 2010 Jul; 25(4):329-34. PubMed ID: 20535068
[TBL] [Abstract][Full Text] [Related]
35. [Metabolic therapy for heart failure].
Loiacono F; Alberti L; Lauretta L; Puccetti P; Silipigni C; Margonato A; Fragasso G
Recenti Prog Med; 2014; 105(7-8):288-94. PubMed ID: 25072544
[TBL] [Abstract][Full Text] [Related]
36. Metabolic therapy for patients with diabetes mellitus and coronary artery disease.
Rosano GM; Vitale C; Fragasso G
Am J Cardiol; 2006 Sep; 98(5A):14J-18J. PubMed ID: 16931201
[TBL] [Abstract][Full Text] [Related]
37. Metabolic therapy for the diabetic patients with ischaemic heart disease.
Rosano GM; Vitale C; Volterrani M; Fini M
Coron Artery Dis; 2005 Nov; 16 Suppl 1():S17-21. PubMed ID: 16340399
[TBL] [Abstract][Full Text] [Related]
38. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine.
Stanley WC; Marzilli M
Fundam Clin Pharmacol; 2003 Apr; 17(2):133-45. PubMed ID: 12667223
[TBL] [Abstract][Full Text] [Related]
39. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy.
Belardinelli R
Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V35-9. PubMed ID: 11206102
[TBL] [Abstract][Full Text] [Related]
40. Role of trimetazidine in management of ischemic cardiomyopathy.
Bertomeu-Gonzalez V; Bouzas-Mosquera A; Kaski JC
Am J Cardiol; 2006 Sep; 98(5A):19J-24J. PubMed ID: 16931202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
